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Methodology 
This report presents the current regulatory framework for human biobanks in Japan 
as it has been set out in two recent sets of guidelines; the ‘Fundamental Principles of 
Research on the Human Genome’, created by the Bioethics Committee of the Council 
for Science and Technology in Japan in June, 2000; and the ‘Ethical Guidelines for 
Analytical Research on the Human Genome/Genes’, issued on March 29
th
 2001 by the 
Japanese Ministry of Health, Labour and Welfare, the Ministry of Education, Culture, 
Sports and Technology and the Ministry of Economy, Trade and Industry. Where 
appropriate, these Guidelines are contrasted and compared with the proposed UK 
Biobank Ethics and Governance Framework, and points of convergence and 
significant differences between the Japanese and British approaches are highlighted.  
In addition to close textual analysis of these Guidelines, illustrations from Japanese 
civil law, as well as excerpts from Japanese primary legislation and from published 
secondary materials have also been included in this report. An attempt has been made 
to critically present the main streams of thought in the Japanese academic literature, 
and to draw out possible weaknesses or areas of uncertainty within the Japanese 
approach, as well as its strengths. Where Japanese language materials have been 
used, the standard procedure of producing a phonetic translation of the Japanese in 
roman lettering, followed by a translation into English has been followed. Whilst 
every effort has been made to ensure the accuracy of Japanese-English translations, 
the author accepts full responsibility for any changes in nuance which may have 
occurred. 
Executive Summary 
Regulators drafting the legal and ethical framework of the UK Biobank Project are 
attempting to achieve a complex and delicate balance of interests. The regulatory 
structure which they devise must maximise the usefulness of the Biobank as a long-
term resource for a variety of population-based genetic studies. At the same time, 
regulators must also strive to protect the rights and dignity of the donors of genetic 
material on whose highly-sensitive information this research will be based. When 
weighing the various competing interests, it may be useful to observe the ways in 
which other jurisdictions have attempted to regulate human genetic databases- to 
analyse the successes and problems of their regulatory frameworks and see how 
behaviour has evolved in those countries in practice. Viewed in this spirit, Japan may 
prove to be a valuable and informative case study in the regulation of human 
biobanks. 
In both Japan and the United Kingdom, the state-sponsored development of the 
bioinformatics sector has increased the need for public trust and support for medical 
research, and in both Japan and the U.K., this has come at a time when public faith in 
the medical and research communities is at a particularly low point following a series 
of high-profile medical scandals. Further factors have raised significant additional 
challenges for the drafters of the Japanese guidelines, giving them perhaps an even 
more arduous task than that of their British counterparts. Privacy concerns amongst 
the Japanese general public are perhaps even more acute than in the UK, due to 
hypersensitivity about potential genetic discrimination and the general aversion in 
Japanese society to discussing the issues raised by inheritable disease. Western 
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(primarily American) concepts of bioethics have been introduced into Japan only 
relatively recently, and while some medical professionals have actively sought to 
reduce paternalistic attitudes and to integrate more patient-centred decision making 
into their clinical practice, leading Japanese bioethicists have nevertheless been 
critical of the current rather limited reception of bioethical principles amongst the 
Japanese medical and research community. The perception in the eyes of the 
Japanese public of a medical research community which is reluctant to change in 
spite of widespread pressure serves only to further entrench the current atmosphere of 
mistrust. Some observers have suggested that the combination of these factors will 
likely serve to discourage public participation in biobank projects in Japan. 
In order to demonstrate some credible mechanism for protecting the rights of 
research subjects and win back a degree of public trust, two sets of guidelines have 
recently been introduced in Japan to regulate the collection, utilisation and storage of 
human genetic material: the ‘Fundamental Principles of Research on the Human 
Genome’, created by the Bioethics Committee of the Council for Science and 
Technology, which was published in Japan in June, 2000; and the ‘Ethical 
Guidelines for Analytical Research on the Human Genome/Genes’, issued on March 
29
th
 2001 by the Japanese Ministry of Health, Labour and Welfare, the Ministry of 
Education, Culture, Sports and Technology and the Ministry of Economy, Trade and 
Industry. Both sets of Guidelines aim to achieve public understanding and to develop 
a secure and fair environment for genetic research. The two major themes which run 
through both sets of Guidelines are autonomy and privacy; these have been 
articulated in the forms of informed consent and anonymisation respectively.  
However, despite providing fairly detailed guidance with regards to the duty to obtain 
full informed consent and to protect the privacy of research participants, some 
Japanese commentators have pointed out that a number of issues have not been 
entirely resolved by the two sets of guidelines. Firstly, it has been suggested that the 
current guidelines grant too much power to individual Ethics Review Committees, and 
fail to set clear limits on the exercise of their discretion. Secondly, the current 
guidelines have also been criticised for not giving sufficient attention to the issue of 
the precise circumstances under which samples may be linked to research subjects 
and correlated with medical records, environmental data and other personal 
information which could potentially be used to identify a particular individual, and 
the conditions under which such sensitive data may be transferred to external 
organisations or subcontractors. Thirdly, some observers have pointed to the fact 
that these guidelines are not hard law but gyosei shido (administrative guidance) - a 
commonly-used Japanese administrative technique which is often favoured in fast-
moving areas such as biotechnology, where formal legal regulation is frequently 
perceived to be too restrictive. Although the Ministry of Health does back its 
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guidelines with the threat of sanctions such as the withdrawal of research funds from 
institutions which violate its provisions, it is unclear what normative impact the 
guidelines will have on private research institutes which are not dependent on state 
funding.  
At a broader social level, the regulatory culture surrounding biomedical issues in 
Japan has also been criticised, as the current lack of public debate and discussion 
about advances in human genetics is seen by some as being symptomatic of an overly 
paternalistic culture towards decision-making and policy in the medical sphere. Many 
observers have suggested that there is an urgent need for more public engagement 
with regards to biobanks and their benefits in order to win public support and 
understanding. The UK Biobank project has been cited in Japanese academia as 
being laudable in this respect.   
Nevertheless, the UK Biobank and similar projects such as Generation Scotland can 
perhaps learn from some elements of the Japanese regulatory framework. 
Particularly interesting features of the Japanese regime are the control mechanisms 
of the requirement of detailed research protocols which must be approved by the 
Ethics Review Committee before research can proceed, and the institutionalisation of 
the interaction between individual researchers, head researchers and Ethics Review 
Committees. Furthermore, the designation of dedicated information protection 
managers in Japan to anonymise samples and to ensure participants’ privacy by 
storing biological samples separately from medical records and other information 
which could potentially identify participants, and the rules for withdrawal of consent 
(both by the individual concerned and their representatives) are also noteworthy 
aspects of the Japanese regulatory approach. One significant divergence from the UK 
Biobank regulatory framework is a Japanese participant’s right to know his or her 
genetic information, where this is technically feasible, with provisions made for 
genetic counselling where this is appropriate. Discussions are still continuing on the 
issue of when and how to provide health information to participants in the UK 
Biobank. Finally, the example presented in this report of Kyushu University’s 
commitment to benefit sharing with participants may help to overcome some of the 
current negative publicity surrounding medical research in Japan, and give credence 
and credibility to the Fundamental Principles’ stated objectives of making a genuine 
contribution to the health and welfare of participants and to society as a whole. 
1.  Regulating Biobanks in Japan 
1.1  Current Biobank Activity in Japan 
The Japanese Government has identified the growth and development of its 
biotechnology industry as being vital to ensuring Japan’s continued economic 
prosperity in the 21
st
 Century. Biotechnology’s privileged status prompted the 
Japanese Government to initiate its “Basic Strategy Towards the Creation of 
Biotechnology Industry” in 1999, which provides substantial funding to a number of 
projects designed to enhance both the international competitiveness of Japan’s biotech 
sector and to apply scientific advances to bring benefits to the health and welfare of 
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the Japanese population." The ‘Basic Strategy’ is coordinated by five ministries and 
agencies, including the Science and Technology Agency, the Ministry of Agriculture, 
Forestry and Fisheries, and the Ministry of International Trade and Industry. Through 
sizeable investment in strategic areas, the programme aims to create 1000 Japanese 
biotechnology companies and a market worth 25 million yen (approximately 118 
billion GBP) by the year 2010.# In the post-genome-sequencing era, it appears that the 
advancement of Japanese technical capabilities in the area of bioinformatics has been 
assigned a particularly high priority. The various ministries aim to consolidate 
existing genetic analysis projects and use them as the foundation for further ‘post 
genome’ informatics research. Much of the current wave of bioinformatics work 
focuses on research into Single Nucleotide Polymorphisms (SNPs)- variations of a 
single nucleotide believed to be the cause of most phenotypical variations from hair 
colour to disease susceptibility. Researchers believe that mapping SNPs will assist in 
the understanding and analysis of human disease and drug response. As the racial 
background of the Japanese is relatively homogeneous and as some SNPs which are 
prevalent in the Japanese population are not commonly found amongst Caucasians, it 
is consequently believed in Japan that the investigation of “Japanese SNPs” should be 
pursued as a discrete unit of study. 
1.2  The “Millennium Projects” 
As part of this overarching strategy, the biotechnology-related component of the 
Japanese Government’s ‘Millennium Projects’-a five-year plan targeting areas of 
science and technology with high economic potential- aims to provide financial 
investment to create a multitude of new SNP databanks and to consolidate and 
incorporate a number of earlier bioinformatics and database projects (which were 
initiated in the pre-genome-sequencing era of the late 1980’s and early 1990’s) into 
larger databases. Of the new databases being assembled, the BioBank Japan Project 
and the Japanese contribution to the International HapMap Project are perhaps the 
best known, but a number of smaller studies administered under the auspices of the 
Millennium Projects also promise to further knowledge significantly in the field of 
human genomics. 
1.3  The BioBank Japan Project 
With obvious similarities to the UK Biobank, the large-scale BioBank Japan Project is 
designed to study sets of ‘high-value’ SNP markers against genetic samples from 
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approximately 300,000 Japanese individuals over a five-year period./ The project 
commenced in April 2000 as a collaboration between the Human Genome Centre 
(HGC) at the Institute of Medical Sciences, Tokyo University (IMST)9 and the 
		+;	$-6-	;. The project’s objective is to identify up to 
150,000 SNPs prevalent throughout the human genome within two years and to 
develop analytical tools for research into genetic polymorphisms. The BioBank Japan 
Project team is being led by Dr. Yusuke Nakamura, director of IMST's Human 
Genome Centre and group director of the Research Group for Personalized Medicine 
at the RIKEN Genome Science Centre.! Dr. Nakamura is also the principal 
investigator for Japan on the International HapMap Project. 
1.4   The International HapMap Project 
The International HapMap Project is a worldwide initiative intended to create a map 
of common patterns of SNPs.  The Project is a collaboration between scientists in the 
U.S National Institutes of Health (NIH), the RIKEN Genomic Sciences Centre in 
Japan, and research institutes in the U.K., Canada, China and Nigeria."  The Project 
officially started with a meeting on October 27-29, 2002, and is expected to be 
completed within around three years.# The goal of the initiative is to analyse human 
SNPs in an effort to identify haplotypes, or sets of associated SNP alleles in a region 
of a chromosome, that can be utilised to further understanding of human disease.  
1.5  Other BioBank Projects and Initiatives 
In addition to the high-profile Japan Biobank project and the Japanese contribution to 
the International HapMap, there are a large number of other state-sponsored 
bioinformatics and biobank projects currently in operation at an estimated 40-50 
research institutions. Other Millennium Projects include various SNPs databases to 
conduct research into specific diseases, such as cancer, dementia, high blood 
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pressure/, asthma/allergy and diabetes9. Major national databases include many that 
were established in the pre-genome era of the 1990’s, including GenomeNet!, the 
Protein Research Foundation, the DNA Databank of Japan", the Kazusa cDNA# 
database, RIKEN’s new Human Organised Whole Genome Database ‘HOWDY’ 
/and the Japanese Collection of Research Bioresources (JCRB)./  
Another recent observable trend is the increasing input of the private sector in 
genomic research projects. The “Pharma SNPs Consortium” (PSC) was set up in 
September 2000 to investigate the role that specific SNPs play in the onset of 
common genetic diseases and conditions and to apply the knowledge gained to the 
design of tailor-made pharmaceuticals with reduced side-effects./ Forty-three 
Japanese pharmaceutical companies will participate in the project, and will collect 
blood samples from a target number of 1,200 volunteers. Research themes include: 
the location of single nucleotide polymorphisms in a pharmacokinetics-related gene; 
the frequency of SNP emergence in the general Japanese population, and; the analysis 
of the expression and function of the mutation-type protein generated under the 
influence of SNPs. A database will be built to accommodate research results and after 
the filing of patents, the data will be open to the public. The research period will be 
for three years with a total investment of 1 billion Yen (approximately 5 million 
pounds). Professor Nakamura of IMST (above) has been appointed as Director of the 
project.// 
A further category of databases are the “private collections” among researchers of 
universities and medical research institutes who have been pooling samples while 
undertaking research programmes funded by Monbusho and the Ministry of Health 
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and Welfare (MHW). As a general rule, these institutions tend not to share their 
samples beyond their groups or institutes./  
1.6  The Final Goal- Towards a Comprehensive Database? 
Stuart observes that in the coming years, the final goal of the Millennium Projects 
seems to be to consolidate the information contained within the ‘first generation’ 
databases and collections of cells, tissues and genes, and to integrate these data (as 
well as that obtained by current biobank projects), into a single, ‘comprehensive 
database’. However, it appears that at the current time there is no universally clear 
idea amongst those involved as to the exact motives for developing such a database or 
as to the precise applications to which it would be put./9 
1.7  Fostering Public Trust and Encouraging Participation 
In Japan, as elsewhere, the success of these and subsequent biobank projects depends 
not only on the quality of the science and technology to be applied in genetic analysis, 
but also upon the ability to secure public participation- an issue which in turn hinges 
upon engendering public trust. When viewed from this perspective, Japan’s current 
push into bioinformatics development comes at something of an inopportune moment 
for the Japanese Government, as trust in the medical profession is at an historic all-
time low./! A number of high profile medical scandals have severely undermined 
public faith in the ethical integrity of the once-highly respected medical 
establishment, which is now generally perceived by the Japanese public as being 
‘unable to regulate itself’./  
A further important factor which may discourage biobank participation in Japan is the 
fear of genetic discrimination in the context of marriage, employment and insurance. 
This anxiety is highly accentuated in Japan, where hereditary disease has traditionally 
been stigmatised and even discussion of hereditary disease is generally shunned./" In 
the last few years, incidents of medical institutions selling patient’s medical 
information (complete with full medical history, address and telephone number) to 
pharmaceutical companies and pharmacies have not helped engender public trust with 
regards the way the medical profession protects confidential information./# The 
Japanese Medical Association has issued repeated warnings that this particular 
attitude towards genetic disease in Japan, combined with the current mistrust with 
which Japanese medical and research professionals are regarded, is likely to result in a 
general reluctance to participate in genetic research programmes, particularly if a 
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credible and secure system of personal data protection cannot be demonstrated to the 
Japanese public.  
1.8  The Japanese Regulatory Framework for Human Biobanks 
In order to bring much needed harmonisation and uniformity to this patchwork of 
ethical standards, two sets of guidelines have recently been introduced in Japan to 
regulate the collection, utilisation and storage of human genetic material: the 
‘Fundamental Principles of Research on the Human Genome’ (the Fundamental 
Principles), created by the Bioethics Committee of the Council for Science and 
Technology in Japan in June, 2000; and the ‘Ethical Guidelines for Analytical 
Research on the Human Genome/Genes’ (the Ethical Guidelines), issued on March 
29
th
 2001 by the Japanese Ministry of Health, Labour and Welfare, the Ministry of 
Education, Culture, Sports and Technology and the Ministry of Economy, Trade and 
Industry. Both sets of Guidelines aim to achieve public understanding and to develop 
a secure and fair environment for genetic research. Both the Fundamental Principles 
and the Ethical Guidelines bear a degree of similarity to the broad principles outlined 
in the UNESCO Declaration on the Human Genome and Human Rights.  
Two major themes which run through both sets of Guidelines are autonomy and 
privacy, which have been articulated in the forms of informed consent and 
anonymisation. The most salient points shared by the guidelines are: 
i. The use of informed consent forms to mediate almost all aspects of the 
relationship between researchers and research subjects; 
ii. The consultation at all stages between research subjects and individual 
researchers or research groups, the head of research institutions and Ethics 
Review Committees. Research must proceed upon the authorisation of the 
Ethics Review Committee and the permission of the heads of the research 
institute. Ongoing progress reports regarding the research, as well as its 
results, must be reported to the Ethics Committee; 
iii. The decision as to whether or not to participate in a programme of research 
should not result in any difference in terms of therapeutic treatment for an 
individual, and consent may be withdrawn with no prejudicial effects towards 
the subject during such time period as withdrawal is possible; 
iv. Measures for the anonymisation and protection of personal data must be 
implemented; 
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v. The donation of biological materials is voluntary and without financial reward. 
Furthermore, intellectual property rights and other economic benefits which 
may arise as a result of the research will not be attributed to the participant. 
Although the Guidelines set the parameters for further information collection, they are 
not retrospective. The Guidelines are not intended to apply to clinical laboratory tests 
designed to obtain genetic information for direct therapeutic benefits to the subject or 
his/her blood relatives. Nevertheless, it is stipulated that such tests and analyses of the 
human genome should be properly conducted with due respect for the aims of the 
present Guidelines and with reference to other guidelines established by relevant 
organisations. 
2.  Understandings and Consent 
2.1 Recruitment 
Participation in Japanese Biobanks and genome research will be entirely voluntary, 
and the collection of blood and tissue samples etc. for research purposes may only 
proceed once the participant has given his or her informed consent./ This notion of 
voluntary participation is further reinforced by Section 1 Principle 5 (“Basic 
Conditions”) of the Fundamental Principles, which states that “[a]n individual who is 
requested to provide a research sample but does not consent to that request should not 
be disadvantaged as a result of his/her refusal.”  
The selection process itself must be fair and rational, and the reason why a candidate 
is being invited to take part in a genome research project should be disclosed to both 
the prospective participant and the Ethics Review Committee overseeing the research 
project.9 If a candidate for participation has or is suspected to have a disease or a 
medical abnormality such as an abnormal drug response, the candidate should be 
informed of the name of the disease or be given an equivalent description of the 
abnormality.! At the current time it is still unclear whether or not genetic researchers 
in Japan will attempt to enlist suitable research participants through coordination and 
collaboration with general practitioners. 
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INFORMED CONSENT OF PARTICIPANTS IN GENETIC RESEARCH 
2.2 The Reception of the Doctrine of Informed Consent in Japan 
Despite Japan being a signatory to the 1964 Helsinki Declaration  and a number of 
other international instruments, the integration of the concept of respect for patient 
autonomy, with informed consent as its primary expression, has been a slow and 
gradual affair." It appears that as a normative matter, there remains significant 
diversity with regards to the degree of importance attached to the doctrine amongst 
members of the medical community. More traditional and conservative institutions 
have shown little enthusiasm for change from more paternalistic approaches to patient 
care.  
Nevertheless, in recent years, a number of rulings from the Supreme Court have 
finally established informed consent as a legal matter within Japanese medical 
jurisprudence. In a 1981 ruling, the Japanese Supreme Court stated that physicians 
have a legal duty to explain the nature and the risks involved with the surgery which 
is to be carried out, and can only proceed once consent has been obtained.# A further 
significant legal development occurred in a 2000 Supreme Court ruling, where 
damages were awarded purely for mental suffering as a result of the breach of the 
duty to obtain informed consent (and with no claim with regards physical harm) in a 
case where a doctor performed a blood transfusion on a patient despite her 
autonomous decision not to undergo the transfusion due to her religious beliefs.9 
Nevertheless, some observers suggest that the doctrine is still at an early stage of its 
reception. Rihito’s criticisms of the limited understanding of informed consent would 
suggest that the acknowledgement of informed consent as a legal matter in Japan has 
not necessarily been uniformly translated into behavioural change or normative 
consensus with regards to the degree of significance that should be attached to the 
doctrine in a clinical setting.9 However, this situation is perhaps likely to change in 
                                                 
  ;$ I+ :+	 6	 	  8, =$	 7	  :+	 E	$
F..-8
*
)1	++)$"$I:636*)8,5+
#!
+ 
) *++   
	$  *+ 	 ) $ #$ I:6 3 6*)
;,  @	) # 9C /9$ I:6 3 6*) 	 F @	) #"/C  I:6
36*)8-A-*)#"#C"$I:636*)*IE
)	
 
$ 6	 @	) ##! + $ 9+I:63 6*) =+)
-$ 	+ @	)
	7-$#+++)$I:636*)I$-
"   I+ B' $*- $%&&'''$
*'+	1&1,&1	&)$* 
.+*)
#
*
$'9!#"!#E
-	9
9 
*
 E
-8    # . 	 9 	 " E
-  
	# ;1*<,
)	
3	)
 ,	'	
 "	) "4	-	 "5
	
 " 4 
("-	2	 ", 
!)
'	 	-  
##@$
*
 
-'$	$
+	
$+
*	
+$
*
$'!#"!9/
-#!	#
$	   
+  +
  *  )
 $*+	 
'$ $  )-
++	+-		C$
-$
*

8 ##99.		#	!/-
++)$
	'$	$	
*+$)*+	+*-
9A*
EF*-8$+$;+:+	(B$	7	.

 6	

	
   / ##   #/( .) (  $%&&''')$	1&	$$# L#(
1$* E$A*
7B$	 +D' I+4.  $
G * . +.	  )$	 + $ 		+ $ *+ 
++-  *+
(2004) 1:3 SCRIPT-ed 
 
460 
light of the aforementioned Supreme Court rulings, perhaps more for defensive legal 
reasons than because of unanimous agreement amongst the Japanese medical and 
medical research community on the normative and ethical significance of respecting 
patient autonomy.  
This ambivalence with regards to informed consent has been even more apparent in 
the conduct of ex-vivo medical research, with a number of incidents demonstrating 
what appears to be the complete lack of any kinds of ethical controls or respect for 
individual autonomy when gathering blood and tissue samples. For example, in 2000, 
researchers at the National Cardiovascular Centre in Osaka, the University of Kyushu, 
Fukuoka, and Tohoku University, Sendai, all admitted that they had used thousands of 
blood samples for analysis without obtaining prior informed consent from patients.9 
Events such as these received considerable attention in the Japanese media, further 
compounded public mistrust and fuelled the perception that the Japanese medical and 
scientific community has little regard for patient/subject rights, and is generally 
“unable to govern itself”.9/ A particular fear amongst Japanese researchers is that 
without a credible legal framework for the protection of subject’s interests, a lack of 
support from the Japanese public will force Japanese scientists to gather their samples 
and conduct research in other countries where coherent legal controls have ensured 
willing public participation.9 At least one leading Japanese geneticist has complained 
of difficulties in obtaining tissue samples for research due to the scarcity of willing 
donors.99  
The two sets of guidelines therefore come as a move to construct a framework which 
will enable scientists to conduct effective research while simultaneously protecting 
the rights of research subjects. Both sets of guidelines give extensive details with 
regard to the types of consent needed before DNA samples may be obtained and 
genomic analysis can be undertaken. 
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2.3  Defining Informed Consent in the Context of Genomic Research 
The central importance of informed consent in the context of genomic research is 
enshrined in Chapter 2, Section 1 (Informed Consent), Principle 5 “Basic Conditions” 
of the Fundamental Principles, which states that:
“A research sample may be collected from an individual subject for 
research on the human genome only after the participant has first 
been given a sufficient explanation of the research, and has given, of 
his/her own free will, his/her informed consent…..The consent 
should be expressed in writing”. 
The Ethical Guidelines define informed consent in the following way: 
“The consent voluntarily given for provision and handling of 
samples etc. by research subjects who are requested to provide them 
after having been explained in detail beforehand by the chief 
researcher about the significance, objectives and methods of 
planned research, anticipated outcomes and inconveniences and 
other relevant information and having fully understood such details. 
The present Guidelines require that informed consent be obtained in 
writing”. 
This definition of informed consent can be deconstructed to reveal the following three 
component elements: 
i. A duty to explain: When the researcher is obtaining informed consent, the 
objectives, methods and potential outcomes of the research, and also any 
disadvantages and losses that the participant might incur should be explained 
in a clear and understandable way.9" 
ii. A duty to ensure that the patient has understood the explanation: The 
person who explains the proposed research to the participant, for the purpose 
of obtaining their informed consent, should be careful that the participant 
fully understands the experiments in which his/her sample will be used, and 
the significance of the act of providing the material.9# When obtaining consent 
researchers should take into account the fact that participants do not always 
have a good knowledge of research on the human genome. For this reason, 
explanations should be given in several steps, each time confirming that the 
participant has understood up to that point. An explanation using written 
material, for example, is desirable because it can give the participants as much 
time as they need before they make a decision to consent, and can indicate 
particular points for reflection.!  
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iii. A duty to obtain informed consent in writing: The consent should be given 
in writing and a suitable record kept. However, if a participant has difficulty or 
is unable to consent in writing for a particular reason, such as difficulty in 
writing or motor functions, appropriate alternative methods, e.g. audio-visual 
recording, should be prepared. Alternative methods should be chosen in place 
of written consent only if there is such an impediment for the participant, and 
not for the sake of convenience for the researchers.! 
A detailed explanation of the issues that must be specifically included in the informed 
consent form can be found in the Ethical Guidelines’ “Bylaw regarding the contents 
of the written information for informed consent”, which is attached in Appendix I. The 
proposed contents of the consent form for participants in the UK Biobank are attached 
as a point of comparison in Appendix II. 
2.4 The Scope of Consent & ‘Comprehensive Consent’  
A recurrent problem with the use of the doctrine of informed consent in biobank 
projects is that often at the time that consent is given, it is not (nor cannot be) totally 
clear precisely what the subject is consenting to. This is particularly an issue in Japan, 
where it is anticipated that the same biological samples may be utilised in a number of 
genome analysis studies or integrated within larger databases. As a general principle, 
when participants grant consent they are consenting to the researcher carrying out 
research specifically within the framework of the particular research project that has 
been explained and outlined to them. Nevertheless, due to the value of samples to 
researchers, the Fundamental Principles permit a significant softening of the 
strictness of this requirement by permitting researchers to obtain ‘comprehensive 
consent’; where consent is granted not only to a specific and defined project, but to 
which the consent granted extends to other genome analysis or to other related 
medical research. Typically this will mean that the subject will consent to the use of 
their samples in a specific and defined research project, and also that they consent to 
the use of their samples for ‘studies aimed at other purposes’.! The requirements for 
obtaining comprehensive consent are further elaborated in Principle 8 1.(b) of the 
Fundamental Principles, which provides that: 
“In this case, sufficient information, which clearly outlines the 
anticipated objectives of the research at that point in time, should be 
given to the participant so that s/he can thoroughly understand the 
significance and consequences of the fact that the sample provided 
will be used in “studies aimed at other purposes…” 
In accordance with the general principle of obtaining informed consent outlined in the 
previous section (2.3), detailed information should be given about other genome 
analyses and related medical research that are anticipated at that time, regardless of 
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whether any of them are actually undertaken later. Nevertheless, the explanatory notes 
go on to stress that “comprehensive consent should not be solicited simply for the sake 
of convenience or saving of labour.” The control mechanism at this stage is the Ethics 
Review Committee, which must approve the research protocol and the type of 
informed consent to be obtained. The temptation to obtain comprehensive consent as a 
way to gain a free hand to use research samples can thus only be tempered by an 
Ethics Review Committee. In any event, a research project requiring comprehensive 
consent should not be approved by an Ethics Review Committee unless the 
confidentiality of the personal information of the participant (including genetic 
information and identifying information) is guaranteed.! It is also reiterated in 
Principle 8 paragraph 1.(c) of the Fundamental Principles that protocols pertaining to 
the management and protection, including anonymity, of genetic and other personal 
information of the participant should be explained in detail, and that strict 
confidentiality should be guaranteed.  
2.5 The (Re-)Use of Existing Samples 
The issue of whether samples which were obtained before the two sets of Guidelines 
came into force can be re-used in new genomic studies has also been addressed. 
Principle 9 of the Fundamental Principles establishes a general prohibition on the use 
of existing samples (obtained before the coming into force of the Fundamental 
Principles i.e. June 14
th
, 2000) in new genetic research projects. Under the strictest 
interpretation of Principle 9, such samples “should be destroyed immediately”, along 
with any research results exclusively deriving from them.!9 However, the subsequent 
section of Principle 9 then goes on to detail in fairly broad terms the circumstances 
under which researchers may derogate from these guiding principles.!! The Ethical 
Guidelines provide more detail and divide existing samples, such as tissues cells, 
body fluids and excretions, and the DNA extracted from them, into three categories 
(group A, B & C samples) with regards the scope of the consent under which they 
were obtained and the criteria that must be satisfied before they can be re-used in new 
projects of genome and genetic analysis. 

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Principle 9(3) of the Fundamental Principles gives some guidance as to how Ethics 
Review Committees should evaluate requests from researchers to authorise the reuse 
of group A, B, or C samples in new genetic studies, stating that: 
“…if the research to be undertaken  requires the use of an existing 
sample for which informed consent was not obtained at the time of 
provision, or if the research to be undertaken is beyond the scope of 
the consent obtained, the said sample should not be used prior to the 
proposed research undergoing a review by the Ethics Committee. 
The Ethics Committee should determine the conditions for the use of 
existing samples, including requirements for re-obtaining informed 
consent, taking the following points into consideration: the 
anonymity of the sample, the possibility of linking the sample to the 
donor, the nature of the sample, the research plan and details of the 
said research, the potential impact on the participant, et cetera, and 
measures for the protection of personal information.”: 
The issue of the scope of informed consent was a significant point of contention in the 
discussions on the UK Biobank Ethics and Governance Framework. Opinion was 
divided on the question of whether the Biobank could legitimately adopt a pragmatic 
approach whereby broad consent (i.e. consent to participate in UK Biobank with all 
that that implies!#) would be obtained, enabling the Biobank to then utilise the sample 
in a wide-range of genetic studies, or whether under the strictest interpretation of the 
principle of autonomy underpinning the Helsinki Declaration, it would be necessary 
to obtain specific consent from participants for each and every research project 
making use of their samples and data in order for the consent to be valid and for the 
Biobank project to be ethically acceptable.  Most commentators on the 2003 UK 
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Biobank Ethics and Governance Framework agreed that as long as sufficient 
explanation was given at the time of obtaining consent and participants then freely 
agreed to “participate in the UK Biobank and all that that entails”, there would be no 
need to go back to the participants to obtain new consent for each and every proposed 
genetic study.  In addition to this imposing significant logistical and financial 
burdens upon the UK Biobank and being unduly troublesome to participants who may 
not want further contact, recontact would not be necessary as most genetic research 
undertaken using the Biobank would fall within the scope of the broad consent given 
by participants (even though this would not constitute full and informed consent). On 
this point, the Nuffield Council on Bioethics’ views on the ethical acceptability of 
genuine consent, even if that consent is not necessarily fully informed, are highly 
instructive: 
“The ethically significant requirement is not that consent be 
complete, but that it be genuine. Ensuring that consent is genuine is 
mainly a matter of care in detecting and eliminating lack of 
consent…Obtaining genuine consent requires medical practitioners 
to do their best to communicate as much as patients, volunteers or 
relatives can understand about procedures and risks, and to respect 
the limits of their understanding, and of their capacities to deal with 
difficult information. If all reasonable care is exercised, adequate 
and genuine consent may be established, although it will necessarily 
fall short of fully informed consent.” 
Nevertheless, in order for the consent to indeed be genuine in accordance with the 
Nuffield Council’s definition, some commentators believe that procedural 
mechanisms should be established to deal with the small number of particularly 
sensitive kinds of research projects (for example, behavioural genetic research) or 
requests for access to Biobank data by particular kinds of researchers (for example, 
the tobacco industry) which may fall outside the scope of even broad consent. / The 
reaction in Iceland to the control of the Icelandic Health Sector Database being 
transferred to a private company illustrates that although many people may be willing 
to provide samples and allow access to their medical records for a public venture 
which aims at improving the health and welfare of the nation, these sentiments may 
not necessarily equate with a willingness to participate in research undertaken by 
commercial organisations aimed at generating profits.  Under the current proposed 
regulatory regime for the UK Biobank, if and when such ethically sensitive situations 
were to arise, the Ethics and Governance Council would decide whether or not access 
to the database should be granted, and if so, whether the particular research proposal 
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falls outside the scope of the broad consent granted and if participants need to be 
recontacted and new consent obtained. 9  
Although in fact a similar mechanism of obtaining broad consent with the safeguard 
of an Ethics Review Committee to identify research proposals which fall outside the 
scope of consent was also adopted in Japan, these issues of sensitive kinds of research 
or the ethics of certain kinds of private sector research have not drawn much 
discussion in Japan, and in contrast to the UK Biobank position, no mention of the 
fact that the resultant databases may be used by commercial entities needs to be made 
in the informed consent form. ! As with the situation in the UK, it remains open to 
speculation quite how Japanese Ethics Review Committees will evaluate requests for 
access to genetic and medical data for use in potentially sensitive studies and to what 
extent the Japanese public would oppose the use of their genetic samples and medical 
information in certain kinds of (private sector) research. 
2.6 Collection of Data From Medical Records 
The UK Biobank will gather medical information and the medical records of 
participants and correlate this information with ongoing genetic analyses. This process 
is generally seen as a valuable aid in enabling researchers to “complete the health 
picture” and to increase the richness and accuracy of their analysis. The intention to 
link participants’ samples to their medical records in the UK will be stated at the time 
of obtaining consent. One perhaps surprising aspect of genomic research in Japan is 
that at the current time there do not appear to be any plans to gather detailed 
information regarding donor’s lifestyle patterns, medical records and environmental 
factors for correlative research, even in an anonymised form. Stuart suggests that this 
anomaly can be explained by the aforementioned fear of discrimination and the 
hypersensitivity to the stigma related to genetic congenital disease in Japan.   
However, Masui and Takada have suggested that research on samples alone without 
correlation to medical records and environmental conditions is likely to be of limited 
scientific value, and have called for further discussion and clarification on the precise 
conditions and procedures for correlative research in order to ensure that a robust 
system for protecting privacy is in place. " It seems that clarification on this key issue 
will emerge from subsequent discussions between Ethics Review Committees and the 
Ministry of Health. # 
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2.7 Provision of Health Information to Participants 
It is likely that some participants in genetic research studies may want to know the 
results of the analysis of their samples and the implications that this is likely to have 
for their health. Some participants may even expect this feedback as part of the quid 
pro quo for participation. Principle 13 of the Fundamental Principles establishes the 
general rule that each individual participant has the right to know about his/her own 
genetic information resulting from the research." This should be explained to the 
participant when obtaining consent" If at the stage of initial enrolment it is discovered 
that the participant has a disease such as a monogenic disease, the explanation given 
to the participant or their representative should include information about the use of 
genetic counselling and he/she should be given access to genetic counselling as 
needed." The “bylaw regarding contracting out part of research without 
anonymisation” in the Ethical Guidelines states that the chief researcher should either 
explain to the participants “regularly and as wanted”, or make public the “progress, 
status and the results of analytical research” on their genetic information."/ 
However, at this point it is important to bear in mind that the term “results” in this 
part of the Ethical Guidelines seems to be referring to the information which arises as 
a primary “result” of the particular genetic research project being carried out by 
researchers, rather than to imposing a duty on researchers to provide “results” in the 
form of individual clinical diagnoses. Thus in many cases, even if a participant 
exercises his/her right to be informed of the results of the research, this will not 
always mean that the participant can obtain practically useful information, or that the 
participant will even be able to fully understand the meaning of the information 
disclosed." On this issue, the Fundamental Principles state that: 
“It is desirable that the researchers or medical practitioners fully 
explain to participants the meaning and usefulness of the genetic 
information obtained from the research, and the differences between 
research and diagnosis, and that they urge participants to 
understand and judge for themselves, before exercising their right to 
be informed, how genetic information arising as primary result of 
research differs from any diagnoses coming from the interpretation 
of that information.”: 
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The Fundamental Principles further elaborate upon the distinction between genetic 
research and clinical diagnosis, stating that: 
“[a]s mentioned above, evaluation of the significance of each result 
of the research belongs in the domain of clinical diagnosis and is 
beyond the limit of the present Fundamental Principles…… 
Guidelines should be drawn up separately for genetic diagnoses.”: 
Some exceptions to the rule that a Japanese participant has the right to know about 
his/her genetic information are elucidated in the Fundamental Principles and in the 
Ethical Guidelines. In the following cases, genetic information need not be disclosed 
to the participant: 
1) In the case of large scale research projects, analytical research on the human 
genome/ genes is conducted to reveal a relationship between a certain disease 
and a gene or the function of a certain gene by comparing the genetic 
information of a large number of people or genes, and the genetic information 
of a single participant is not sufficient by itself to confer accuracy or reliability 
on a diagnosis of the condition of health or other medical aspects of the 
participant and thus disclosure to the participant would not be of sufficient 
significance. This decision should also be approved by the Ethics Committee."  
2) If the sample has been anonymised during the course of the research and can 
no longer be identified with the donor."" 
In contrast, the general policy adopted by the UK Biobank is that of not informing 
participants of the results of ongoing research. This is due to the logistical difficulties 
involved and the higher legal ‘duty of care’ that would be imposed on providers of 
clinical diagnoses as opposed to researchers merely taking samples."# However, some 
observers in the UK have expressed discomfort with a possible scenario of researchers 
becoming aware of a participant having a serious medical condition for which a 
treatment is available, but then being prevented from disclosing this information to the 
participant and informing them of the risk because of the Biobank’s information 
disclosure policy. As a compromise, it appears that exceptions to the general principle 
of not informing participants of the results of genetic analysis may be developed. This 
could perhaps entail UK Biobank participants being informed of any clinically 
relevant findings elicited during the initial consultations with the Biobank research 
nurse and then being asked to contact their GP about those findings.# However, it 
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appears that the issue of feedback to participants is still undergoing consideration 
within the UK.# 
2.8 The Right Not to be Informed 
As a general principle, the participant has the right not to be informed of his/her 
genetic information resulting from genetic research, and the findings of the research 
may not be made known to the participant against his/her will. # Researchers are 
under an obligation to explain to subjects about their right not to be informed when 
obtaining consent. However, the Ethical Guidelines also contain a provision which 
permits researchers to override the participant’s desire not to be informed in situations 
when it would be in the participant’s best interests to be informed of the results of 
genetic analysis.#/ Factors to be taken into account by the Ethics Review Committee 
when making its deliberations include: 
a) The availability of effective therapeutic measures;  
b) The likelihood of the participant’s blood relatives having the same disease or 
medical problem; 
c) The effect on the lives of the participant’s blood relatives and the health 
condition of the participant’s blood relatives; 
d) The stipulation of informed consent pertaining to disclosure of the research 
results. 
2.9  Proxy Consent and Consent from those with Reduced Capacity 
As a general rule under the Japanese regulatory framework, samples should not be 
taken from an individual who lacks the capacity to consent (e.g. if they suffer from a 
condition such as dementia or if they are a minor), nor should samples be used from 
the deceased. However, this is qualified by an exemption which allows researchers, in 
cases where the study is of significant social benefit and could not be undertaken 
without a sample from the specific individual lacking capacity to consent, to take 
proxy consent from a representative.# Whether or not an individual has the capacity 
to consent should be judged in as scientifically and objectively a manner as is 
possible. Thus, a medical practitioner who is unconnected with the research in 
question should make the actual decisions from an objective standpoint. Principle 6 of 
the Fundamental Principles stipulates that “an individual incapable of giving his/her 
own consent should not be involved whenever the research could be conducted 
equally well without the participation of that individual”.#9 Once an Ethics Committee 
has given approval to proxy consent, researchers may contact the potential 
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participant’s representative, and obtain full and informed consent in accordance with 
the general consent rules described above.#! 
The ‘Bylaw regarding the basic idea about the selection of the participant’s 
representative’ in the Ethical Guidelines provides that the chief researcher should 
select the participants’ representative from the following persons in the following 
order, with due consideration given by researchers to the participant’s particular 
familial structure: 
a) The participant’s spouse; adult offspring; a parent; an adult sibling or 
grandchild; a grandparent; a relative living together; a person considered 
equivalently close to the participant.  
b) A voluntary guardian; a person with parental authority; a lawful guardian or an 
assistant.#  
The procedures to select the representative should be clearly described in research 
plans and undergo the review of the Ethics Committee. When giving consent on 
behalf of the participant, the representative should take sufficient precautions that the 
rights and interests of the participant are protected and would not be infringed. In a 
case when the participant is a minor above a certain age, it is desirable that consent 
also be obtained from the participant him/herself. There are no provisions in the two 
sets of guidelines for advance directives by future participants before they become 
incapacitated. 
2.10  The Withdrawal of Consent 
In Japan, under the Fundamental Principles and the Ethical Guidelines, the rights of a 
research subject to withdraw their consent for the use of their samples and resultant 
data in a project hinges upon the issue of whether a particular sample can be linked to 
the individual who donated it.#" In principle, consent can be withdrawn at any point 
without disadvantage to the participant if the sample can still be attributed to its 
donor. In these cases, the sample itself and the data derived exclusively from it should 
be destroyed.## However, consent cannot be withdrawn once the sample has become 
unidentifiable, it is no longer linked to its donor, or it is stored in such a way that the 
linking is impossible. 
This information about the right to withdraw consent, and its limitations, should be 
given in advance of obtaining the donor’s informed consent. When the period of 
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preservation of samples etc. as prescribed in the research protocol has elapsed, the 
chief researcher should destroy them in accordance with the conditions agreed on with 
the participants or their representatives. This provision, however, does not apply to 
cases where samples etc. are preserved by the chief researcher himself or provided to 
a human cell, gene or tissue bank. Consent cannot be withdrawn for samples that are 
stored in banks or are commercially available. The research results need not be 
destroyed in instances where they have already been made public./ 
The two sets of Japanese guidelines do not make any provision for individual 
participants to selectively opt out of individual projects involving a particular kind of 
research, nor are there any alternatives to complete withdrawal of consent to 
participate, such as the model of discontinued participation proposed in the UK 
Biobank Ethics and Governance Framework.  
2.11  Withdrawal of Consent by the Relatives of a Deceased Research Subject 
The issue of whether the relatives of a deceased participant in a Biobank can exercise 
control over their deceased relative’s samples and medical records by withdrawing the 
original consent for participation was considered in a 2004 ruling by the Supreme 
Court of Iceland.9 The court held that the daughter of a deceased research subject 
who participated in a biobank had legal standing to prevent the right to prevent the 
transferral of their relatives’ medical data into a genetic database. The Court’s 
reasoning was founded upon the argument that as the plaintiff and her deceased father 
both shared genetic characteristics, the information in the database would allow 
inferences to be made about the plaintiff herself, and therefore her father’s medical 
records fell within the scope of personal information protected by the plaintiff’s 
constitutional-protected right to privacy.!  
Although the Japanese guidelines predate the Icelandic Supreme Court ruling, they 
follow a similar pattern of reasoning. The Japanese approach is to stress that 
researchers should respect the feelings and wishes of the participants surviving family 
and give due consideration to the fact that genetic information of a dead person is 
shared by his/her blood relatives.  Consequently, the appointed representatives of the 
participant may also withdraw their consent for the use of the participant’s sample in 
accordance with the above-mentioned principles. The dead participant’s 
representative should be a person who is considered to be able to represent the will 
that the dead participant was supposed to have while alive. The participant or his/her 
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representative can withdraw their consent at any time without penalty by expressing 
the intention of doing so in writing. When consent has been withdrawn, the chief 
researcher should in principle anonymise and destroy the samples, etc. provided by 
the participant and the research results concerning the participant." However, it is not 
entirely clear if the relative of a deceased research subject will first have to be 
appointed by the chief researcher of a research institution as a representative before 
he/she can exercise this right. How this mechanism will operate if the institution 
refuses to appoint the surviving relative of the deceased as the representative, or how 
institutions should prioritise competing interests if a conflict should emerge amongst 
relatives is a point for further discussion.    
As with the withdrawal of consent by the participant themselves, a number of 
limitations apply to a representative’s right to withdraw from a research project. 
Consent can not be withdrawn if research samples have been anonymised so that they 
cannot be linked to the participant, or if there is very little possibility that personal 
information could be elicited from them if they were not destroyed and it would be 
prohibitively expensive to destroy the samples, or if the research results have already 
been made public.# 
3. Privacy 
3.1  The Protection of Personal Medical Data in Japan 
As the analysis of genetic information can reveal an individual’s current physical 
condition and their predisposition for developing genetic disease, there is the fear that 
these highly sensitive data could be used to discriminate against individuals in the 
context of employment or insurance. This anxiety is highly accentuated in Japan, 
where inheritable disease has traditionally been stigmatised and where even public 
discussion of the issues raised by inheritable genetic disorders is generally shunned. 
The Japanese Medical Association has issued repeated warnings that this particular 
attitude towards genetic disease in Japan, combined with the current distrust with 
which Japanese medical and research professionals are regarded, is likely to result in a 
general reluctance to participate in genetic research programmes- particularly if a 
credible and secure system of personal data protection cannot be demonstrated to the 
Japanese public. A number of observers have therefore predicted that the issue of 
privacy, above all others, is likely to be the one which will most significantly shape 
public perceptions of genetic research and analysis in Japan. 
This section describes and analyses the framework for protecting privacy put into 
place by the Fundamental Principals and the Ethical Guidelines. However, before 
moving on to an examination of the privacy rules established by the two sets of 
Guidelines, a brief mention will be made of the 2003 Personal Information Protection 
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Law (Japan), and the duty on medical professionals to protect the confidentiality of 
patient’s personal information set out in Japanese criminal law. 
3.2 The Japanese Data Protection Law 2003 
The Japanese Data Protection Law, which passed the Japanese parliament in May 
2003, is the first statute to comprehensively regulate the use of information in the 
private sector in Japan./ The law places controls on the way in which personal 
information is collected and retained, and prevents the disclosure of personal 
information to third parties without the consent of the individual concerned. However, 
the law itself was designed more specifically to deal with regulating the use of private 
information in the fields of commerce and business than to protect personal medical 
information, and the exemption carved out by Paragraph 50, Section 1, Subsection 3 
of the Data Protection Law excludes academic research from the need to conform to 
the provisions of the Law. Although the paragraph 50 exemption does not specifically 
mention medical information or genetic research, it is generally believed that the Data 
Protection Law does not apply to genetic research. However, at the current time it is 
not clear if genetic research conducted by public/private consortia will also fall within 
the scope of the paragraph 50 exemption of the Data Protection Law. 
3.3 The Legal Duty to Protect the Confidentiality of Patient’s Information 
The medical profession in Japan has long been subject to laws and regulations which 
have placed its workers under a professional duty to protect confidentiality. 
Physicians, pharmacists and midwives have all been regulated by the breach of 
confidence provisions of section 134 of the Criminal Code (Law No.45, enforced in 
1907), Article 100 of the National Civil Service Law (Law No. 120, enforced in 
1947), and other relevant laws. Even those working in the medical field lacking 
professional qualifications have also been subject to separate laws which establish a 
legal duty to protect patient confidentiality. However, the duty to protect the 
confidentiality of patient’s/ research subjects’ medical information is not absolute, and 
a number of exceptions exist whereby physicians may use the data for purposes other 
than those agreed and decided, or pass the information on to third parties in cases 
where this is necessary to preserve human life, health or property; or to maintain 
public health and sanitation or to protect the welfare of children.9 
Having established that the Personal Information Protection Law will have little 
impact on genomic research, but that Japanese physicians were nevertheless already 
under a legal duty to protect the confidentiality of their patient’s records, we now turn 
to examine the regime established by the Fundamental Principles and the Ethical 
Guidelines. 
                                                 
/ A1 $  8-  A 

 8 / ;$  7	 D' /
$%&&''',-1&1&&.	&$
,&$

&// $
$* 		  	 

)
-;;;$'')
	'(-	+:9
A)<$&
&%	&	%
;$7F*7	D'+7
E-$J		K
9//
9F$,'A(	
%%&
&;$	*$*+	
$
/9/		
(2004) 1:3 SCRIPT-ed 
 
474 
3.4 The Commitment to Confidentiality 
One of the key themes permeating both sets of guidelines is anonymity. The Ethical 
Guidelines and the Fundamental Principles both stress that at all points during the 
collection, storage, transfer and utilisation of human biological materials, the 
anonymity and privacy of the research subject must be protected.Principle 11 of the 
Fundamental Principles outlines in broad terms the importance of protecting the 
confidentiality of personal genetic information.! The explanatory notes to the 
Fundamental Principles also impose an obligation on research institutions to establish 
a control system for the safekeeping and protection of the personal information related 
to providing samples, including the separate storage of information which can link the 
sample and the donor.   
The strict confidentiality of personal information is also enshrined as one of the basic 
principles of the Ethical Guidelines, and the duties of researchers and heads of 
research institutions in protecting subject privacy are delineated in considerable 
detail." The basic responsibilities of researchers are described in Chapter 2 of the 
Ethical Guidelines, and are stated as being the protection of personal information, 
efficiently responding to complaints about standards of data governance, and the 
prevention of the disclosure of personal information (unless this disclosure is 
justified).# The sanctions for breaching the provisions of the guidelines with regards 
to maintaining the confidentiality of personal information include the penalties 
described above under the breach of confidence provisions of section 134 of the 
Criminal Code (Law No.45, enforced in 1907), demotion of the researchers involved 
and the withdrawal of research funding. Principle 12 of the Fundamental Principles 
also provides that if a breach of confidentiality occurs, the participant who has 
sustained damages from that disclosure is entitled to receive compensation or 
indemnity. However, these legal remedies are not elucidated in any great detail 
within the Fundamental Principles themselves.  
3.5  The Role and Responsibilities of the Personal Information Manager 
Both the Fundamental Principles and the Ethical Guidelines stipulate that research 
institutes have an obligation to appoint a personal information manager, who will 
manage personal information processing activities and construct a clearly defined 
chain of command for the control of personal information for each research project. 
The personal information manager should be an individual who is legally prohibited 
from disclosing secrets that he/she has come to know in the performance of their 
duty. The personal information manager will also oversee the process of the 
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anonymisation of research samples, is responsible for keeping any identifying 
information stored separately from the sample itself and holds the “keys” to unlock 
anonymised data/samples when requested by researchers and authorised by the Ethics 
Review Committee./  
3.6  The Anonymisation of Research Samples 
As a general rule, all samples should be anonymised before analytical research on the 
human genome/genes is conducted in order to protect and maintain the privacy of the 
participants.The Ethical Guidelines define two types of anonymity: 
a) Relative anonymity, where samples may still be linked to subjects. Samples 
etc. are made unidentifiable, but a table that links them with codes or numbers 
assigned to research subjects is retained to allow identification if necessary. 
b) Absolute anonymity where samples cannot be linked to subjects. Samples etc. 
are made irreversibly non-identifiable without retaining a table that links them 
to codes or numbers assigned to research subjects. 
A two stage process has been constructed for the anonymisation of donor information. 
The first stage of anonymisation occurs when subjects donate materials to medical 
institution, and a second level of anonymisation occurs if this information is 
transferred for incorporation into a larger, central database. In the first stage, samples 
taken and used in research by the medical institution retains information which can be 
used to identify the subject, but the procedures for linkage and the information 
necessary are tightly controlled by the personal information managers.  Stuart 
describes the procedures for anonymisation and holding samples separately from 
identifiable medical and personal information from in the following way: 
“Managers appointed to supervise the protection of donor 
information provide each sample with a unique bar code, containing 
donor information. Details of the coding are kept on a stand-alone 
workstation, protected by fingerprint operated mouse controls and a 
hard disc drive password entry system. Paperwork relating to the 
donors is kept in a high security safe. The bar-coded sample is then 
passed (along with the age of the donor) to the research team.” 
The second stage of anonymisation occurs when research data is transferred into a 
central database. The data, along with the age of the donor, are fed into an online 
computer connected to the central database. Linkable now only by age and under 
normal circumstances amongst an array of data for similar aged donors, the data and 
donor should no longer be unequivocally linkable. Aggregation further reduces the 
chances of the sample being linked to a particular individual.! 
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However, some observers have suggested that perfect anonymisation is extremely 
difficult, and the chance of linking samples to an individual will always exist. 
Whereas this generally constitutes the starting points on discussion regarding 
anonymisation within the UK, the great difference with discussion and debate in 
Japan is that discussion flows from the presupposition that perfect anonymisation is 
possible. This, according to Masui and Takada, influences the quality of the 
discussion in the two countries.  
As mentioned above, one perhaps surprising aspect of genomic research in Japan is 
that at the current time there do not appear to be any plans to gather detailed 
information regarding donor’s lifestyle patterns, medical records and environmental 
factors for correlative research, even in an anonymised form. Stuart suggests that this 
anomaly can be explained by the aforementioned fear of discrimination and the 
hypersensitivity to the stigma related to genetic congenital disease in Japan." Masui 
and Takada have suggested that research on samples alone without correlation to 
other personal and medical information is likely to be of limited scientific value, and 
have called for further discussion and clarification on the precise conditions and 
procedures for correlative research, especially in longitudinal cohort studies, and to 
ensure that a robust system for protecting the privacy of participants is in place.#  
It is unclear under the current guidelines how anonymisation will operate if the same 
institution is carrying on multiple projects, as potential modalities for transferring data 
between projects have not yet been fully elaborated. Stuart observes that in 
circumstances where hospitals are likely to have insufficient patients for a satisfactory 
association study and study methods between researchers vary considerably, useful 
comparisons of data will be difficult to make./ 
3.7  Exceptions to the Principle of Protection of Subject Anonymity 
Although the importance of the anonymisation of research samples is given 
considerable emphasis and is one of the principal mechanisms through which 
confidentiality is maintained, it is nevertheless accepted by the Ministry of Health 
Labour and Welfare that there is value in certain circumstances (e.g. when disease 
related and where an effective method of treatment exists) in being able to link 
research data to the sample donor. In such circumstances, under conditions yet to be 
fully determined and with the authorisation of the Ethics Review Committee, heads of 
research institutes will have the authority to link research data to the sample donor./ 
Where the disease is a hereditary one and beneficial medical intervention is not 
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possible, a decision on whether or not it would be appropriate to permit linkage is also 
currently under review by the MHLW./  
A second exception to the principle of anonymity outlined above is that samples may 
be provided to an ‘outside institution’ or transferred to sub-contractors without 
anonymisation if the participant or his/her representative has consented to provision of 
samples, etc. or genetic information to an outside institution without anonymisation 
and the research protocol, which has been approved by the Ethics Review Committee 
and authorised by the head of the research institution, stipulates the provisions of 
samples, etc. or genetic information without anonymisation.// Here, the issue of 
privacy is to an extent recast as an issue of autonomy. 
The “safe harbour” provisions of the Ethical Guidelines specify that if a Japanese 
research institution engages in joint research with overseas researchers, the Japanese 
personal information managers and Ethics Review Committees must ensure that the 
foreign receiving institution has standards of data governance that are either 
equivalent to or higher than those provided in the Ethical Guidelines before 
authorising the transfer of identifiable data and other sensitive information./  
3.8  Disclosure of Genetic Information to Persons Other than the Participant 
In many cases, informing a specific individual of the results of a test for a genetic 
disorder will have serious implications not only for the individual concerned, but also 
for his/her blood relatives, who may also share the same genetic condition. The 
Fundamental Principles state that at the time of obtaining informed consent, 
researchers should explain to participants about the implications of the result of a 
genetic test for family members, and allow the participant to make a judgement 
beforehand with regards to whether they would wish to inform blood relatives of the 
results of the participant’s genetic analysis or whether they would prefer that this 
information remains confidential.  In the eventuality that a conflict emerges between 
the right of the participant to keep the information private and the right of the blood 
relative to know about their own health, the Japanese regulatory framework maintains 
the flexibility to give priority to the latter./9 Even in cases where participants have 
stated that they do not wish other parties or blood relatives to be informed of the 
results deriving from analysis of their genetic information, if a participant’s genetic 
information has been found to indicate that there is a genetic effect which is very 
likely to endanger the lives of the participant’s blood relatives, and there is an 
effective therapeutic measure to deal with the genetic effect, the Ethical Guidelines 
authorise Ethics Review Committees to permit the disclosure of genetic information 
to the participant’s blood relatives even against the participant’s wishes./! The chief 
researcher should consult with the Ethics Review Committee on the decision of 
whether or not to reveal the information to blood relatives, the extent of the 
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information to be disclosed and the method of disclosure, before informing blood 
relatives. These provisions therefore seems to grant researchers the discretion to 
inform participants of the results of genetic analysis, rather than imposing an 
obligation to inform in all cases. 
As in the UK, scant consideration has been paid in Japan to possible modalities for 
protecting the rights of blood relatives of a research subject who do not wish to know 
their own genetic information, but where informing the research subject of their 
genetic test result will nevertheless often amount to indirectly informing blood 
relatives of their own genetic predisposition to certain diseases./    
4. Relationship with Society 
4.1 Governance Structure and Accountability 
All research institutions in Japan at which analytical research on the human 
genome/genes is conducted are required to install an Ethics Review Committee./" It is 
envisaged that the Ethics Review Committee will oversee all stages of genome 
research and act as the overarching ethical control mechanism, ensuring compliance 
with the guidelines, transparency and accountability. Ethics Review Committees will 
screen all research proposals submitted by researchers and have the power to make 
recommendations to alter research protocols, or even to reject them outright. 
Approved research protocols must be adhered to, and regular monitoring will ensure 
against unethical research practices. The Ethical Guidelines define the role and the 
nature of the interactions between researchers, heads of research institutes and Ethics 
Review Committees. The Ethical Guidelines also provide details regarding the 
composition of Ethics Review Committees, stipulating that Committees should ideally 
be composed of members trained in social sciences and cultural issues, and crucially, 
it is stated that it is desirable that more than half of the members of the Ethics Review 
Committee should be independent of the research institution which it is overseeing./# 
However, this requirement is relaxed with the provision that if the research institute 
encounter difficulties in engaging independent committee members, the number can 
be reduced to one single external ethics reviewer.  
On-the-spot investigations will be conducted at research institutions by outside 
experts to ensure compliance with the guidelines and to confirm that the individual 
research protocols are being adhered to. The head of a research institution must 
send copies of the regular reports on the operational status of research and the reports 
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of on-the-spot inspection by outside experts to the Ethics Review Committee. The 
Ethics Review Committee is in turn obliged to send an annual report on the 
operational status of research projects to the Japanese Ministry of Health, Labour and 
Welfare. The Ministry of Health will review current policy and issue further 
guidance on the basis of the collected reports, and may place information in the public 
domain in order to promote transparency and to promote the public’s freedom of 
access to information./ The adequacy of these arrangements is still being debated in 
Japan. 
4.2  Intellectual Property Rights 
Genetic databases are primarily designed as resources for the statistical analysis of the 
role of specific genes in the onset of genetic disease, and are not expected in 
themselves to lead to patentable inventions that will return significant income either to 
researchers or to the biobanks in the short-term. However, it is anticipated that in 
the medium-to-long-term, research conducted using the data or samples from genetic 
databases may support the development of inventions that generate revenue.9 There 
is also the possibility that biobank researchers may generate cell lines from 
scientifically useful biological samples, which could then be marketed as research 
tools.! Japanese researchers are fully aware of the importance of securing intellectual 
property protection on the results of their research. Japanese patent law permits the 
patenting of biotechnological products and processes on similar terms to the patent 
laws of the United States and the European Union.   
Stuart observes that where the Millenium projects give rise to patentable information, 
such as the identification of the role of certain genes in the pathology of genetic 
disease, the Japanese MHLW, via its Organisation for Pharmaceutical Safety and 
Research (OPSR), will file patent applications. Revenue generated by the intellectual 
property will be divided between OPSR and all those having had an input, including, 
where appropriate, universities, individual research institutes and companies." This 
arrangement is likely to be a powerful incentive to the public sector research 
community.# Given this strong emphasis on the commercialisation and patenting of 
research results as an aspect of Japanese industrial policy, it has been important for 
the two sets of guidelines to attempt to construct a uniform system for the allocation 
of property and intellectual property rights in samples and the valuable genetic 
information contained therein at different stages of research and development. 
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In alignment with the trend in most developed countries, the Fundamental Principles 
elects to resolve any potential uncertainty in this area through the use of the informed 
consent as a mechanism to mediate the relationship between the researcher and the 
participants in relation to property/intellectual property rights and to define the legal 
status of biological materials and the genetic information contained therein. Principle 
17 of the Fundamental Principles states that:       
“Researchers or research institutions can claim intellectual 
property rights such as patent rights based on the results of their 
research. A participant who simply provides a research sample 
cannot claim intellectual property rights relating to the sample, 
since the value of those intellectual property rights is brought about 
by scientific actions of the researchers, or by the ingenuity of those 
persons who make use of the outcomes of that research, and is not 
attributable to the provided sample or to the genetic information 
contained in it. It is desirable that it be made clear to participants, 
at the time that their informed consent is obtained, that they cannot 
automatically claim the intellectual property rights.” 
Principle 17 of the Fundamental Principles (Gratuitousness and related principles) 
then goes on to state that when researchers are obtaining written informed consent, 
there explanation must contain a statement to the effect that i) research samples 
should be provided gratuitously; and ii) in the event that an outcome obtained as a 
consequence of a research project becomes the subject of intellectual property rights 
or other rights, these rights are not attributed to the participant.9  
It is unclear how a case with similar facts to Moore v. The Regents of the University of 
California, where researchers filed patents on commercially valuable excised 
biological material without the subject’s knowledge or consent, would be decided 
under the provisions of Japanese law.9 To date, there have not been any cases in 
Japan which have explicitly considered the issue of whether an individual has 
property/ intellectual property rights over biological materials extracted from their 
body, nor is the potential conflict of rights which may arise in such a case clarified by 
being specifically addressed in any Japanese legislation. Similarly, the Japan Patent 
law does not contain any provision equivalent to Recital 26 of the Biotechnology 
Directive, which states that a participant from whose body the biological material is 
taken must have had an opportunity of expressing free and informed consent in 
accordance with national law.9  
In an attempt to address this complex and nebulous question, Sumikura points out that 
according to Article 246 of the Japanese Civil Code, when a person has added their 
workmanship to the property of another person, the ownership of that work 
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nevertheless still belongs to the original owner of the materials.9/  However, Article 
246 also states that when the economic value resulting from that workmanship far 
exceeds the value of the original materials themselves, the person adding the 
workmanship acquires ownership of that work. Since research materials such as cell 
lines used as research tools would generally have far greater economic value as a 
result of manipulation by a researcher than would the extracted materials themselves 
in their ‘raw’ state, Sumikura suggests that it may be reasonable to tentatively 
conclude that their ownership would therefore lie with the researcher rather than with 
the source of the biological materials in question. However, Sumikura also suggests 
that if a case with similar facts to Moore were to be decided in Japan, a judge may 
take the view that a research subject in a certain sense, ‘owns’ the biological materials 
extracted from their body (in terms of traditional property rights rather than registered 
patent rights) until they are conveyed or title is transferred through conferring 
consent.9 As stated above, it seems likely that if the issues of intellectual property 
rights are explained and dealt with in the consent form, there will be no need for a 
Japanese court to consider these questions. 
4.3 Dissemination of Information 
With regards to the dissemination of information and research results in general, the 
two sets of guidelines state that in principle, the results of research should be publicly 
disclosed, in line with the stated objective of improving the health and welfare of 
humanity and of each human being.99 The proviso which applies here is that the 
confidentiality of research results may be maintained for the time period in which it is 
reasonable to do so in order not to compromise intellectual property rights or for other 
purposes relating to ongoing research.  The UK Biobank Ethics and Governance 
Framework has a similar statement, but also contains a particular emphasis on the 
publication of negative findings and the development of a system for the “archiving of 
such materials.”9! 
4.4  Benefit Sharing 
One of the points related to the legal ownership of biological samples is the issue of 
whether payment should be paid to the sample donor. Sumikura states that although it 
could be argued that a monetary expression of appreciation could be paid to donors of 
blood samples in order to promote research of gene analysis, this is equivalent to 
assigning a monetary value to samples originating from the human body, and is 
generally viewed in Japan as being ethically improper and in violation of the principle 
of altruism which has traditionally governed the collection of biological samples.9  
                                                 
9/ 
*,
A	$ 

'	 ( " (23 - ,  2	 	)2"
.0-
 	)0
2	 
)*+$E
+)+	
B$	F
F7E4.*)+-
"+#:	$/
9()+
991)	-	2
'
7	92
'4
'"'-"	'	)""
'

9!4AB),=$	+3.	5*',B	,-
+	
*7+)$F*
6+. 3
  =$	 + 3.	  @	) / /  =$	 + 3.	
5*',*)/"'-- 
9 
*,
	9/
(2004) 1:3 SCRIPT-ed 
 
482 
This is essentially the same position adopted by the UK Biobank Interim Advisory 
Group on Ethics and Governance which stated in a 2003 report that it saw “no issue” 
in regards to whether participants should receive remuneration for participation in the 
Biobank- “the expectation simply needed to be stated: Volunteers should not expect to 
be paid for their participation in UK Biobank.”9" 
Neither the Fundamental Principles nor the Ethical Guidelines mention specific 
provisions for benefit sharing of the profits of genetic research with research 
participants, other than that the beneficial results of the scientific research itself will 
benefit to society. However, Kyushu University has taken the lead on this issue in a 
pioneering example of benefit sharing with the inhabitants of the town of Hisayama in 
Fukuoka, where the University been conducting health-related studies for over thirty 
years. A recent study has been commenced to investigate the genetic factors involved 
in lifestyle-related illnesses using the genetic information and medical data of local 
residents, and the University decided to reinvest income generated from any patents 
filed to provide educational activities and to improve the health and welfare of the 
local residents.9# Sumikura considers the Hisayama project and its benefit sharing 
structure to be an ethically laudable means of compensating sample donors following 
the patenting of research results.! Kyushu University’s commitment to benefit 
sharing is also consistent with the principles of solidarity and reciprocity expressed in 
the Fundamental Principles and the Ethical Guidelines, and may help to overcome 
some of the current negative publicity surrounding medical research in Japan. 
5 Adequacy of the Current Guidelines and Possible Future 
Developments 
Despite the Fundamental Principles and the Ethical Guidelines being described by the 
Japan Pharmaceutical Association as “the strictest in the world” with regards to the 
regulation of genetic research, the two sets of guidelines have attracted some 
criticisms within Japan, most notably from the highly influential Japanese Medical 
Association (JMA)! The JMA has publicly stated that the current regulations are 
“[u]nclear on who owns genetic data, and leave too much discretion to advisory 
committees.”!  
Since the publication of the two sets of Japanese guidelines, the methodology used to 
collect medical information in one particular epidemiological study has drawn a 
particularly hostile response from the JMA.!/ Criticisms stemmed from the fact that 
the work of collecting personal lifestyle data for a cancer study of 6,000 residents of 
Kumano-cho, a small town near Hiroshima, was contracted out to ordinary citizens 
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who were under no legal obligation to protect the confidentiality of the information 
they were handling. The relevant provisions of the Ethical Guidelines state that 
personal information managers and assistant personal information managers must be 
individuals who have a legal duty to maintain the confidentiality of medical 
information, and must establish a clearly defined chain of command with privacy 
ensured at each stage.! However, no mention is made of the requisite status of staff 
employed to assistant in the collection of information in genetic studies, and whether 
or not they must also be individuals who are under a legal duty to maintain the 
confidentiality of medical information. It has been suggested that the two sets of 
Guidelines contain several such areas of potential uncertainty, and that occasional 
revisions to the guidelines to clarify specific issues are expected.!9 The JMA’s 
comments are indicative of the current distrust between physicians and clinical 
researchers in Japan.!! In his analysis of the JMA’s motivations, Masui has stated that 
he believes that the JMA is attempting to use this particular incident to exert political 
pressure on the relevant Ministries and clinical researchers in order to “win a greater 
say for physicians in planning and reviewing such projects.”!  This dispute is likely to 
continue, but in the meantime, the fact that this incident was widely reported in the 
Japanese media will likely have a negative impact upon public perceptions of the 
current standards of privacy protection in genetic research. 
The adequacy of the methods for the enforcement of the guidelines has also been 
called into question in Japan. Although the Ministry of Health does back the current 
guidelines with the threat of sanctions (such as the withdrawal of research funds from 
institutions which violate the Ethical Guidelines) it is unclear what normative impact 
the guidelines will have on private research institutes which are not dependent on state 
funding.!"  Some commentators have stated that in addition to the guidelines, formal 
legislation backed with legal sanctions is urgently needed to regulate the collection, 
storage and use of human biological materials and genetic information. However, at 
the current time, the legislative will to implement such a measure does not appear to 
exist.  
The example of benefit sharing in this report is consistent with the stated goal of the 
Fundamental Principles of making a significant contribution to the life and health of 
humanity and each individual, and to the welfare of society.!# This gesture of 
goodwill may also go some way to overcoming some of the negative publicity and 
scepticism surrounding genetic research. Whether or not Kyushu University’s 
pioneering commitment to benefit sharing will inspire other research projects remains 
to be seen. 
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The regulatory framework for the UK Biobank has been described as being “at an 
early stage in its evolution”, with many areas lacking in detail.  This observation 
could perhaps just as easily be applied to the current Japanese regulatory provisions, 
where it seems that decisions on a number of sensitive ethical questions will made by 
individual Ethics Review Committees on a case-by-case basis. Stuart observes that 
further clarification of key issues of data governance, such as determining the scope 
of informed consent, the reuse of samples, the linking of samples to participants’ 
medical records and the transfer of identifiable information to external organisations 
without anonymisation is likely to emerge from further dialogue between individual 
Ethics Review Committees and the Japanese Ministry of Health Labour and 
Welfare.   
At a broader social level, Stuart has observed that attitudes towards bioethics are 
currently in something of a transitional stage in Japan. Observers have pointed to the 
uneasy coexistence between American-influenced concepts of bioethics (with an 
emphasis on individual autonomy), and the more paternalistic, traditional Japanese 
concepts of ethics (rinri), which Masui and Takada summarise as being the 
understanding that “people in positions of responsibility possess knowledge which is 
correct, and we should be grateful when receiving the benefits of their wisdom.”  
Both the effectiveness of the current regime for the regulation of human biobanks in 
Japan and the continuing evolution of Japanese attitudes towards bioethics require 
close monitoring over the coming years. 
APPENDIX I 
Model Japanese Consent Form
Excerpt from the Ethical Guidelines for Analytical Research on the Human 
Genome/Genes, Issued by the Ministry of Education, Culture, Sports, Science and 
Technology, the Ministry of Health, Labour and Welfare and the Ministry of 
Economy, Trade and Industry, on March 29
th
 2001. 
Chapter 3. Basic Attitude to Participants, (8) Informed Consent. 
Bylaw Regarding the Contents of the Written Information for Informed 
Consent. 
The written information given to the participant or his/her representative should in 
general include the following topics, which may vary depending on the nature of 
research: 
1) That the donation of samples, etc. is voluntary. 
2) That the person requested to donate samples, etc. may refuse the request 
without any penalty. 
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3) That the participant or his/her representative may withdraw his/her informed 
consent at any time without penalty by expressing the intention of doing so in 
writing.  
4) That with the participant's or his/her representative's withdrawal of informed 
consent, the samples, etc. donated by the participant and the research results 
concerning the participant will be destroyed unless they are unlinkably 
anonymised. 
5) The reason for being selected as a participant.  
6) The significance, purpose and procedures of the research (The target disease, 
analytical methods, etc. should be mentioned. If any, expected additions or 
alterations of the research plan should also be mentioned. If a disease such as a 
monogenic disease is targeted, the importance of the research, measures to be 
taken to prevent disadvantage to the participant, etc. and other issues peculiar 
to the disease should be mentioned.), and the research period. 
7) In the case where it is difficult to obtain the participant's own informed 
consent, the importance of the research and the reason why the donation of 
samples, etc. by the participant is essential to the research. 
8) The name and post of the chief researcher. 
9) The expected outcomes of the research and the foreseeable risks or 
inconveniences to the participant, etc. (including inconveniences in social life 
such as social discrimination). 
10) That the participant or his/her representative can, if so wishes, have access to, 
or have copies of, documents concerning the research plan and the research 
procedures to the extent that the confidentiality of personal information 
concerning the participant, etc. and the originality of the research may not be 
jeopardized.  
11) Whether the samples, etc. donated and the genetic information derived from 
them will be anonymised linkably or unlinkably, and the concrete procedure of 
anonymisation. If anonymisation is not to be conducted, the fact with the 
reason for it. 
12) Whether or not the samples, etc. donated or the genetic information derived 
from them will possibly be provided to an outside institution. If the samples, 
etc. or the genetic information will possibly be provided to an outside 
institution, that the Ethics Review Committee has approved the procedure of 
handling personal information, the outside institution to which the samples, 
etc. or the genetic information is to be provided, and the purpose of use of the 
samples, etc. or the genetic information at the outside institution. 
13) In the case where part of the research is contracted out to a third party, the 
method of anonymisation, etc.  
14) Matters related to disclosure of genetic information. 
15) That the outcomes of the research may possibly produce intellectual property 
rights such patent rights in the future, and the party to whom such intellectual 
property rights will belong. 
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16) That the genetic information derived from samples, etc. may be presented in 
an anonymised form in academic meetings, etc. 
17) The methods of preservation and use of samples, etc. 
18) The method of preservation, use or destruction of samples, etc. after the 
research (including the possibility of being used for another research and the 
expected purpose, etc. of the research). 
19) In the case where samples, etc. will possibly be provided to a human 
cell/gene/tissue bank for general research use, the academic significance of the 
bank, the name of the organization managing the bank, the method of 
anonymisation of the samples, etc. to be provided to the bank, and the name of 
the head of the bank. 
20) Information about the use of genetic counselling (In the case where the 
participant has a disease such as monogenic disease, that genetic counselling is 
available to the participant, etc.). 
21) The source of the research funds. 
22) That provision of samples, etc. is gratuitous. 
23) Information about participant relations such as the person or office to contact    
when the participant, etc. have questions, complaints, etc. 
APPENDIX II 
Proposed Model Consent Form for Participants in the UK Biobank  

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1. Consent 
Consent will be sought “to participate in UK Biobank”. Participation will be cast as an 
opportunity to contribute information that in the long term may enhance other 
people’s health. Because it will be impossible to anticipate all future research uses, 
strong governance and safeguards will be in place to protect participants’ interests and 
the public interest. 
Consent will be based on an explanation and the understanding of, amongst other 
things: 
• the purpose of UK Biobank 
• the fact that UK Biobank is not a healthcare programme but a research 
resource 
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• the kinds of information and samples that will be collected at enrolment, 
which may include data that some participants might consider especially 
sensitive 
• the fact that there will be a link to the full medical record, past and ongoing 
• the fact that UK Biobank will be the legal owner of the database and the 
sample collection, and that participants have no property rights in the samples 
• the kinds of safeguards that will be maintained, including storage of data and 
samples in reversibly anonymised form, and severe restrictions on access to 
data and samples that are not anonymised 
• the policy for making decisions on research access 
• the assurance that only research uses that have been approved by both UK 
Biobank and an NHS Multi-centre Research Ethics Committee (MREC) will 
be allowed, and that data will be anonymised before being provided to 
research users 
• the expectation that commercial entities will apply to use UK Biobank 
• the possibility of being recontacted in future, by whom and for what purposes 
• the need for UK Biobank to retain as many participants for as long as possible 
in order to maximise its value as a research resource 
• the intention to continue to hold and allow research access to data after 
participants lose mental capacity or die, as such data are crucial for research 
resource 
• the right to withdraw at any time without having to give a reason, and the 
meaning of withdrawal 
• UK Biobank’s commitment to maintaining active engagement with 
participants and society in general. 
The points listed above are some elements of what it means “to participate in UK 
Biobank”; each is discussed in more detail later in the Framework. These elements 
and other customary undertakings will be addressed in particular information and the 
consent process. 
UK Biobank will endeavour to make sure that participants understand what they are 
consenting to. Ways of doing this may be tested in an independent evaluation of the 
consent process used during the pilot phase. 
The consent to participate in UK Biobank will apply throughout the lifetime of UK 
Biobank unless the participant withdraws. Further consent will be sought for any 
proposed activities that do not fall within the existing consent. 
